Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
202 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Radiation Toxicity - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape. Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively. Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology). - The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview 9 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 16 Products under Development by Universities/Institutes 20 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment 21 Assessment by Target 21 Assessment by Mechanism of Action 24 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development 31 Aeolus Pharmaceuticals Inc 31 Angion Biomedica Corp 31 Atox Bio Ltd 32 BCN Biosciences LLC 32 Bolder Biotechnology Inc 33 Cellerant Therapeutics Inc 33 Cellphire Inc 34 Chrysalis BioTherapeutics Inc 34 Cleveland BioLabs Inc 35 Daiichi Sankyo Company Ltd 35 FirstString Research Inc 36 Foresee Pharmaceuticals LLC 36 Galera Therapeutics Inc 37 Genzyme Corp 37 GNI Group Ltd 38 Humanetics Corp 38 Insys Therapeutics Inc 39 Meabco A/S 39 Neumedicines Inc 40 Nohla Therapeutics Inc 40 Onconova Therapeutics Inc 41 Original BioMedicals Co Ltd 41 PharmaIN Corp 42 Pluristem Therapeutics Inc 42 RDD Pharma Ltd 43 Reata Pharmaceuticals Inc 43 RedHill Biopharma Ltd 44 RxBio Inc 44 Shuttle Pharmaceuticals LLC 45 SK Chemicals Co Ltd 45 Soligenix Inc 46 Synedgen Inc 46 Tonix Pharmaceuticals Holding Corp 47 TSRL Inc 47 viDA Therapeutics Inc 48 Windtree Therapeutics Inc 48 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles 49 (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 49 A-02 - Drug Profile 50 AB-103 - Drug Profile 51 ABC-294640 - Drug Profile 54 AEOL-10171 - Drug Profile 61 Aerosurf - Drug Profile 62 amifostine - Drug Profile 67 amifostine - Drug Profile 68 AVMOC-001 - Drug Profile 69 BB-3 - Drug Profile 70 BBT-007 - Drug Profile 74 BBT-015 - Drug Profile 75 BBT-018 - Drug Profile 76 BBT-059 - Drug Profile 77 BCN-057 - Drug Profile 78 BIO-300 - Drug Profile 79 BMX-001 - Drug Profile 82 BPC-2 - Drug Profile 84 C-2E2 - Drug Profile 85 C-2E5 - Drug Profile 86 Cell Therapy for Acute Radiation Syndrome - Drug Profile 87 cerium oxide - Drug Profile 88 CLT-009 - Drug Profile 89 Des-Asp Angiotensin 1 - Drug Profile 90 DG-3 - Drug Profile 91 entolimod - Drug Profile 92 EWA-001 - Drug Profile 99 Fibrinoplate-S - Drug Profile 100 FP-045 - Drug Profile 101 Granexin - Drug Profile 102 HSJ-0017 - Drug Profile 104 JP4-039 - Drug Profile 105 LGM-2605 - Drug Profile 107 m-2A2 - Drug Profile 108 MDY-1001 - Drug Profile 109 molgramostim - Drug Profile 110 NAS-911 - Drug Profile 111 NMIL-121 - Drug Profile 113 omaveloxolone - Drug Profile 117 ondansetron hydrochloride - Drug Profile 120 ondansetron hydrochloride CR - Drug Profile 121 Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile 128 pirfenidone - Drug Profile 129 PLXR-18 - Drug Profile 131 Preimplantation Factor - Drug Profile 138 QR-205 - Drug Profile 139 RDD-2007 - Drug Profile 140 recilisib sodium - Drug Profile 141 Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile 143 Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile 144 Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile 145 Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile 146 RP-239X - Drug Profile 147 RS-9 - Drug Profile 148 rusalatide acetate - Drug Profile 149 Rx-100 - Drug Profile 153 sargramostim - Drug Profile 155 SGX-201 - Drug Profile 158 SGX-202 - Drug Profile 159 SKI-2162 - Drug Profile 162 Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile 163 Small Molecule for Radiation Toxicity - Drug Profile 164 Small Molecule for Radiation Toxicity 1 - Drug Profile 165 Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile 166 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 167 SP-3001 - Drug Profile 168 ST-266 - Drug Profile 169 ST-7 - Drug Profile 172 SY-513 - Drug Profile 173 SYGN-305 - Drug Profile 174 SYGN-399 - Drug Profile 175 Thrombosomes - Drug Profile 176 TNX-701 - Drug Profile 177 TPO-7630 - Drug Profile 178 TPO-7640 - Drug Profile 180 VEDA-1209 - Drug Profile 181 VTI-1000 Series - Drug Profile 182 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects 183 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products 186 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones 187 Featured News & Press Releases 187 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197
List of Tables
Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle Pharmaceuticals LLC, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..1), H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..2), H1 2017 Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
